BioArctic AB (OTCPK:BRCTF)
$ 15.76 -0.0368 (-0.23%) Market Cap: 1.37 Bil Enterprise Value: 1.32 Bil PE Ratio: 0 PB Ratio: 14.20 GF Score: 58/100

Q3 2021 BioArctic AB Earnings Call Transcript

Oct 21, 2021 / 07:30AM GMT
Operator

Hello, and welcome to the BioArctic webcast with teleconference. (Operator Instructions) Just to remind you, this conference call is being recorded. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Thank you, and good morning, and welcome to BioArctic's Third Quarter Report 2020. I I'm Gunilla Osswald and I'm the CEO of BioArctic. I will share this presentation with our CFO, Jan Mattsson. I think it has been a great quarter for BioArctic and lecanemab. Our partner, Eisai, has after discussions with the U.S. FDA initiated a rolling submission for an accelerated approval for lecanemab in the U.S.

If it gets approved, lecanemab could thereby potentially be helping patients even earlier than previously expected, and I will talk more about that in the presentation here today. Next slide, please. BioArctic is listed on nasdaq.com midcap, and this is our disclaimer. Next slide, please.

BioArctic is a unique Swedish

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot